Durvalumab and Tremelimumab before surgery in patients with HR+/HER2-negative breast cancer
A new research paper was published in Oncotarget entitled, "Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer."
Mar 27, 2024
0
0